Senior Advisor at Frazier Healthcare
Sector Expertise: Life Science
Dr. Michael Gallatin joined Frazier Healthcare in 2006 as Venture Partner to the Biopharma team. Previously, Dr. Gallatin was Vice President and Scientific Director of ICOS corporation, a former public biopharma company. Dr. Gallatin's management responsibilities at ICOS included discovery, preclinical research, medchem and process chemistry groups including those that helped generate and support the worldwide registration and launch of Cialis. Subsequently, Dr. Gallatin helped found two Frazier portfolio companies: Cambridge, MA.-based Stromedix, which focuses on novel treatments for chronic fibrotic diseases, and Seattle, WA.-based Calistoga Pharmaceuticals, the first company to demonstrate clinical benefit of isoform selective PI3 kinase inhibition. Calistoga was acquired by Gilead in April 2011 for an up-front payment of $375 million. Dr. Gallatin was President of Calistoga Pharmaceuticals from 2006-2010. He has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry, and a member of the BioSeek Board of Directors.
Dr. Gallatin received his Ph.D. in 1981 from the University of Alberta Department of Immunology. Dr. Gallatin's doctoral research focused on genetic resistance to virally induced neoplastic disease and invasive mechanisms including the first description of antigen gain associated with organ-specific tumor metastasis. While a Damon Runyon-Walter Winchell and American Cancer Society fellow at Stanford University in the laboratory of Dr. Irving Weissman, Dr. Gallatin discovered the first cell adhesion molecule implicated in site selective leukocyte traffic. Dr. Gallatin continued his research in the fields of immunology/inflammation and oncology while on the faculty at the Fred Hutchinson Cancer Center prior to his recruitment by Drs. Chris Henney and George Rathmann as one of the founding scientists at ICOS Corporation in 1990.